ANXA5 and breast carcinoma: In another study, McKernan et al. developed a SWCNT-based new strategy for the treatment of metastatic breast cancer cells by combining the effects of PTT and immunostimulation using annexin A5 (ANXA5)-conjugated SWCNTs and an anti-CTLA-4 check point inhibitor [86].